Genome-wide association studies: How predictable is a person's cancer risk?

Expert Review of Anticancer Therapy

Volumn 9, Issue 4, 2009, Pages 389-392

  Roukos, Dimitrios H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

CANCER GROWTH; CANCER RISK; CANCER SCREENING; DIAGNOSTIC ACCURACY; DNA SEQUENCE; EDITORIAL; GENE DUPLICATION; GENE EXPRESSION PROFILING; GENE LOCUS; GENE MUTATION; GENE NUMBER; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; NEOPLASM; PHENOTYPIC VARIATION; PROGNOSIS; RELIABILITY; SINGLE NUCLEOTIDE POLYMORPHISM; CELL TRANSFORMATION; CLINICAL MEDICINE; FEMALE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETICS; MALE; MEDICAL RESEARCH; METHODOLOGY; PREDICTION AND FORECASTING; RISK ASSESSMENT;

BIOMEDICAL RESEARCH; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL MEDICINE; FEMALE; GENETIC SCREENING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT;

EID: 85047686032     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/eri.11.19     Document Type: Editorial

References (40)

1. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
2. van de Vijver MJ. He YD. van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
3. Huang CC, Bredel M. Use of gene signatures to improve risk estimation in cancer. JAMA 299(13), 1605-1606 (2008).
4. Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J. Clin. Oncol. 27(8), 1337-1338 (2009).
5. Donnelly P. Progress and challenges in genome-wide association studies in humans. Nature 456, 728-731 (2008).
6. Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle - will we get our wish? N. Engl. J. Med. 358(2), 105-107 (2008).
7. Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann. Surg. Oncol. 16, 772-773 (2009).
8. Kaiser J. Breakthrough of the year. It's all about me. Science 318(5858), 1843 (2007).
9. Nowell PC. The donal evolution of tumor cell populations. Science 194(4260), 23-28 (1976).
10. Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther. 6(3), 308-312 (2007).
11. International HapMap Consortium, Frazer KA, Ballinger DG, Cox DR et al. A second-generation human haplotype map of over 3.1 million SNPs. Nature 449(7164), 851-861 (2007).
12. Rockman MV. Reverse engineering the genotype-phenotype map with natural genetic variation. Nature 456, 738-744 (2008).
13. Stern DL, Orgogazo V. The loci of evolution: how predictable is genetic evolution? Evolution 62(9), 2155-2177 (2008).
14. Easton DF, Eeles RA. Genome-wide association studies in cancer. Hum. Mol. Genet. 15(17 R2), R109-R115 (2008).
15. Roukos DH. Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev. Mol. Diagn. 9(1), 1-6 (2009).
16. Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 39, 865-869 (2007).
17. Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies breast cancer susceptibility loci. Nature 447, 1087-1093 (2007).
18. Hunter DJ, Kraft P, Jacobs KB et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39, 870-874 (2007).
19. Eeles RA, Kote-Jarai J, Giles GG et al. Identification of multiple novel prostate cancer susceptibility loci by a genome-wide association study. Nat. Genet. 40, 316-321 (2008).
20. Thomas G, Jacobs KB, Yeager M et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 40, 310-315 (2008).
21. Gudmundsson J, Sulem P, Manolescu A et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39, 631-637 (2007).
22. Gudmundsson J, Sulem P, Steinthorsdottir V et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet. 39, 977-983 (2007).
23. Tenesa A, Farrington SM, Prendergast JG et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat. Genet. 40, 631-637 (2008).
24. Amos CI, Wu X, Broderick P et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40, 616-622 (2008).
25. Study Group of Millennium Genome Project for Cancer; Sakamoto H, Yoshimura K, Saeki N et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet. 40(6), 730-740 (2008).
26. Lee C, Morton CC. Structural genomic variation and personalized medicine. N. Engl. J. Med. 358(7), 740-741 (2008).
27. Roukos DH, Ziogas D. Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the "Gordian Knot"? Ann. Surg. Oncol. 16, 774-775 (2009).
28. Hayden EC. Genome sequencing: the third generation. Nature 457, 768-769 (2009).
29. Roukos DH. Linking contralateral breast cancer with genetics. Radiother. Oncol. 86, 139-141 (2008).
30. Ziogas D, Baltogiannis G, Fatouros M, Roukos DH. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann. Surg. 247(4), 714-715 (2008).
31. Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev. Mol. Diagn. 8(5), 587-597 (2008).
32. Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 358, 197 (2008).
33. Roukos DH. Breast-cancer stromal cells with TP53 mutations. N. Engl. J. Med. 358, 1636 (2008).
34. Zhu J, Zhang B, Smith EN,. Drees B et al. Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks. Nat. Genet. 40(7), 854-861 (2008).
35. Smith EN, Kruglyak L. Gene-environment interaction in yeast gene expression. PLoS Biol. 6(4), e83 (2008).
36. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9(1), 28-39 (2009).
37. Lewis J. From signals to patterns: space, time, and mathematics in developmental biology. Science 322(5900), 399-403 (2008).
38. Bennett CN, Green JE. Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks ana validation of preclinical models. Breast Cancer Res. 10(5), 213 (2008).
39. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41), 5497-5510 (2008).
40. Deisboeck TS, Zhang L, Yoon J, Costa J. In silico cancer modeling: is it ready for prime time? Nat. Clin. Pract. Oncol. 6(1), 34-42 (2009).